Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adiponectin: an update.

M Guerre-Millo1

  • 1Service de nutrition, Inserm U872, hôpital Hôtel-Dieu, 1, place du Parvis-de-Notre-Dame, 75181 Paris cedex 04, France. mguerre@bhdc.jussieu.fr

Diabetes & Metabolism
|December 11, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relevance of increased serum cystatin C to vascular alterations in obese children.

Pediatric obesity·2012
Same author

Adipose tissue inflammation and liver pathology in human obesity.

Diabetes & metabolism·2009
Same author

Promoter adiponectin polymorphisms and waist/hip ratio variation in a prospective French adults study.

International journal of obesity (2005)·2007
Same author

[Is obesity an inflammatory disease?].

Journees annuelles de diabetologie de l'Hotel-Dieu·2006
Same author

The placenta cytokine network and inflammatory signals.

Placenta·2005
Same author

Hyperinsulinaemia triggered by dietary conjugated linoleic acid is associated with a decrease in leptin and adiponectin plasma levels and pancreatic beta cell hyperplasia in the mouse.

Diabetologia·2005
Same journal

Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.

Diabetes & metabolism·2026
Same journal

Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors.

Diabetes & metabolism·2026
Same journal

Two faces of autoimmune hyperinsulinemia: contrasting type B insulin resistance syndrome and exogenous insulin antibody syndrome.

Diabetes & metabolism·2026
Same journal

CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

Diabetes & metabolism·2026
Same journal

Persistent burden and management gaps of hypoglycemia in pediatric type 1 diabetes: insights from the Epi-GLUREDIA Study.

Diabetes & metabolism·2026
Same journal

Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.

Diabetes & metabolism·2026
See all related articles

Leptin and adiponectin are key hormones in metabolic health. Low adiponectin levels are linked to obesity, insulin resistance, and cardiovascular disease, prompting research into ways to boost its effects.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Obesity Research

Background:

  • Leptin and adiponectin, produced by adipose cells, are crucial in metabolic disease research.
  • Leptin regulates food intake and energy balance; its loss causes obesity.
  • Low adiponectin is associated with insulin resistance, type 2 diabetes, and cardiovascular issues in overweight individuals.

Purpose of the Study:

  • To explore the role of adiponectin in metabolic and cardiovascular health.
  • To investigate mechanisms underlying adiponectin's actions and potential therapeutic strategies.
  • To understand how to enhance adiponectin bioactivity and combat low adiponectinemia.

Main Methods:

  • Review of clinical and experimental observations on leptin and adiponectin.

Related Experiment Videos

  • Analysis of adiponectin's multimeric forms, focusing on the high-molecular-weight species.
  • Examination of adiponectin signaling pathways, including AdipoR1 and AdipoR2.
  • Investigation into factors affecting adiponectin gene expression, such as adipose tissue inflammation.
  • Evaluation of pharmacological interventions like thiazolidinediones and cannabinoid-1 receptor blockers.

    • Main Results:

    • Adiponectin exhibits anti-atherogenic and insulin-sensitizing effects, primarily via AMP kinase activation.
    • Adiponectin's actions involve vascular endothelial cells, macrophages, muscle, and liver.
    • Obesity is linked to reduced adiponectin gene expression due to inflammation.
    • Certain drugs (thiazolidinediones, rimonabant) increase adiponectin levels and gene expression.

    Conclusions:

    • Enhancing adiponectin bioactivity is a promising therapeutic avenue for metabolic diseases.
    • Targeting adipose tissue inflammation may reverse adiponectin downregulation.
    • Activating adiponectin receptors (AdipoR) could mitigate metabolic risks in conditions with low adiponectinemia.